Clinical trial · no report yet · Phase 3
SKYSCRAPER-03
A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)
- NCT04513925 ↗
- Completed
- Hoffmann-La Roche
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 17 | |
| Podcasts | 2 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Open-Label, Randomized Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Patients With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer Who Have Not Progressed After Concurrent Platinum-Based Chemoradiation
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- Atezolizumab; Tiragolumab; Durvalumab
- Arms
- Atezolizumab + Tiragolumab · Experimental
- Durvalumab · Active comparator
- Enrollment
- 829
- Primary outcomes
- Progression-free Survival (PFS), as Assessed by an Independent Review Facility (IRF) in Programmed Death-ligand 1 (PD-L1) Positive Analysis Set (PPAS)
- PFS, as Assessed by an IRF in FAS
- Sponsor
- Hoffmann-La Roche
- Start
- Aug 24, 2020
- Primary completion
- May 27, 2025
- Results posted
- Yes
- Registry record
- NCT04513925 · updated Jun 3, 2026